• bioMérieux received FDA 510(k) clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Vaginitis Panel for point-of-care use.
• The test delivers results in about 20 minutes; US commercial launch is scheduled for early 2027, followed by international rollout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMérieux SA published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.